Vioxx Research Today is a free monthly online journal that collates and summarizes the latest research about Vioxx, including details on osteoarthritis, side-effects, trials, stroke, heart attack.

Volume 3 (2006), Issue 2 (February)

1. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
   Arthritis Rheum, 55(1): 27-34. [Abstract] [Full-text]
2. Cyclooxygenase-2 inhibitors: what went wrong?
   Curr Opin Clin Nutr Metab Care, 9(2): 89-94. [Abstract] [Full-text]
3. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
   J Clin Rheumatol, 12(1): 17-25. [Abstract] [Full-text]
4. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors.
   BMC Cancer, 6: 27. [Abstract] [Full-text]
5. Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKalpha-independent manner.
   Diabetologia, 49(3): 562-70. [Abstract] [Full-text]
6. Dexamethasone Impairs the Gastric Mucosal Integrity in Rats Treated with a Cyclooxygenase-1 but Not with a Cyclooxygenase-2 Inhibitor.
   Pharmacology, 76(4): 180-184. [Abstract] [Full-text]
7. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.
   Blood, 107(5): 1785-90. [Abstract] [Full-text]
8. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial.
   Headache, 46(2): 264-75. [Abstract] [Full-text]

© 2004-2008 Vioxx Research Today. All Rights Reserved.